Can docetaxel therapy improve overall survival from primary therapy compared with androgen-deprivation therapy alone in Japanese patients with castration-resistant prostate cancer? A multi-institutional cooperative study
International journal of clinical oncology Volume 18 Issue 1
Page 62-67
published_at 2013-02
Title
Can docetaxel therapy improve overall survival from primary therapy compared with androgen-deprivation therapy alone in Japanese patients with castration-resistant prostate cancer? A multi-institutional cooperative study
Creators
Shimabukuro Tomoyuki
Creators
Sakano Shigeru
Creators
Matsuda Kenji
Creators
Kamiryo Yoriaki
Creators
Yamamoto Norio
Creators
Kaneda Yoshitaka
Creators
Nasu Takahito
Creators
Baba Yoshikazu
Creators
Suga Akinobu
Creators
Yamamoto Mitsutaka
Creators
Aoki Akihiko
Creators
Takai Kimio
Creators
Yoshihiro Satoru
Creators
Konishi Motohiko
Creators
Imoto Katsuhiko
Creator Keywords
Castration-resistant prostate cancer (CRPC)
Docetaxel (DOC)
Androgen-deprivation therapy (ADT)
Overall survival (OS)
Toxicity
Languages
eng
Resource Type
journal article
Publishers
Churchill Livingstone
Springer
Date Issued
2013-02
File Version
Not Applicable (or Unknown)
Access Rights
metadata only access
Relations
[ISSN]1341-9625
[ISSN]1437-7772
[NCID]AA11086579
[NCID]AA11625629
[PMID]info:pmid/22068464
[isVersionOf]
[URI]http://link.springer.com/journal/10147
Schools
大学院医学系研究科（医学）